Clinical trials sponsored by Sun Yat-sen University

Phase breakdown

Conditions studied

Recruiting trials led by Sun Yat-sen University

• A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
  NCT06898385 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery
  NCT06686459 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
  NCT01994057 · Phase: Not specified · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients
  NCT03561740 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
  NCT07088263 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
  NCT06545747 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer
  NCT06520683 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
  NCT06877416 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance
  NCT05528783 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Arsenous Acid for Refractory Triple-Negative Breast Cancer
  NCT06678048 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
  NCT06768931 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 5 locations
• Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
  NCT05962502 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
  NCT06547203 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Clinical Study of Radical Right Hemicolectomy Versus Radical Right Hemicolectomy Combined with Indocyanine Green Fluorescence Imaging Lymphatic Tracer Dissection for the Treatment of Right Colon Cancer
  NCT06485609 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
  NCT05768503 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 12 locations
• Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
  NCT06719700 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Culmerciclib in HR+/HER2+ Advanced Breast Cancer
  NCT07732491 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
  NCT07610720 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Effects of Digital Therapeutic in Whole Process Management of Lung Cancer
  NCT06230445 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
  NCT06529549 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: Male · 1 location
• Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
  NCT06551220 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: Female · 26 locations
• Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
  NCT06582940 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Evaluation of Phacogoniotomy in Medically-controlled POAG
  NCT06201455 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years to 85 Years · Sex: All (male and female) · 1 location
• FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
  NCT05727163 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
  NCT06441565 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
  NCT05334277 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• High Quality Evidence of Chinese Lupus Nephritis (HELP)
  NCT03001973 · Phase: Not specified · Ages: 14 Years and older · Sex: All (male and female) · 1 location
• Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
  NCT07609121 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
  NCT07052669 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Intraoperative Rectal Lavage to Prevent Local Recurrence After Laparoscopic Mid-to-Low Rectal Cancer Resection: A Multicenter Randomized Trial
  NCT07512232 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
  NCT06208371 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
  NCT07448142 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• MItral Regurgitation Risk Assessment and CLinical modElling
  NCT06876883 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer
  NCT06204484 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
  NCT07543536 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• Nanshan Elderly Cohort Study
  NCT03569735 · Phase: Not specified · Ages: 65 Years and older · Sex: All (male and female) · 2 locations
• Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
  NCT05194878 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
  NCT03872661 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
  NCT05011487 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
  NCT06280495 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer
  NCT05571644 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
  NCT06563999 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
  NCT06764680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
  NCT05236972 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
  NCT06977074 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma
  NCT07336979 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
  NCT06268652 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Peritoneal Dialysis Registration System (PERSIST)
  NCT02989298 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers
  NCT06966232 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation
  NCT03671252 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer
  NCT06854250 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
  NCT07477626 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 13 locations
• Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
  NCT06911684 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
  NCT05794971 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD
  NCT07775950 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Risk Factors Affecting MSC Efficacy in ACLF Patients
  NCT07198854 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
  NCT06524427 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · 23 locations
• Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
  NCT07258108 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
  NCT07150247 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients
  NCT06043999 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
  NCT05468242 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer
  NCT05984485 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
  NCT06019455 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
  NCT07644897 · Phase: Phase 2 · Ages: 60 Years and older · Sex: All (male and female) · 2 locations
• Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer
  NCT06903858 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Transanal Total Mesorectal Excision vs Robotic Total Mesorectal Excision
  NCT07651553 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
  NCT05965531 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma
  NCT07750067 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Validation of Insulin Dose Prediction Model Based on Artificial Intelligence Algorithm
  NCT07066891 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
  NCT07012954 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
  NCT06426511 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
  NCT04084496 · Phase: Phase 2 · Ages: 18 Years to 79 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Sun Yat-sen University recruiting for?

Sun Yat-sen University is the lead sponsor of 72 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.